Global Medical Lead, Influenza/RSV, Global Medical Affairs, Sanofi

Since completing her undergraduate, doctoral, and post-doctoral studies at the University of Nottingham in the United Kingdom, Rosalind Hollingsworth has spent nearly 20 years in vaccines medical affairs and clinical research within the pharmaceutical industry.

Rosalind joined Sanofi Pasteur in March 2015. She is currently Global Medical Expert Lead for Influenza and RSV, working with her team to develop and execute the global medical strategy for Sanofi Pasteur’s licensed influenza vaccines and help guide pipeline research and development projects, such as the monoclonal antibody, nirsevimab.

Prior to joining Sanofi Pasteur, Rosalind spent 14 years in Global Medical Affairs at Pfizer with responsibility for pneumococcal conjugate vaccines. Rosalind has also worked with group C meningococcal conjugate vaccines, live attenuated influenza vaccine, transcutaneous vaccine delivery and, beyond vaccines, antibiotics (tigecycline and piperacillintazobactam).

Rosalind’s early research focused on an evaluation of host and viral factors which could influence the rate of progression and clinical outcome of hepatitis C virus infection, with post-doctoral research on early vaccine candidates for the prevention of group B meningococcal disease.